Arsenic trioxide (ATO) has been shown to be the most effective single agent in acute promyelocytic leukaemia (APL) and has been approved for the treatment of relapsed patients both in the US and Europe. The role of ATO in front-line therapy of APL is under investigation.
Breccia, M., Cicconi, L., LO COCO, F. (2014). ATRA + ATO: Has a new standard of care been established in low-risk acute promyelocytic leukaemia?. CURRENT OPINION IN HEMATOLOGY, 21(2), 95-101 [10.1097/MOH.0000000000000023].
ATRA + ATO: Has a new standard of care been established in low-risk acute promyelocytic leukaemia?
LO COCO, FRANCESCO
2014-01-01
Abstract
Arsenic trioxide (ATO) has been shown to be the most effective single agent in acute promyelocytic leukaemia (APL) and has been approved for the treatment of relapsed patients both in the US and Europe. The role of ATO in front-line therapy of APL is under investigation.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.